Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic/Pharmacodynamic Study of Sunitinib in Metastasized Renal Cell Carcinoma
DRKS00005220Phase 4Not yet recruiting
- Sponsor
- Central European Society for Anticancer Drug Research
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC) and renal pelvis cancer, sponsored by Central European Society for Anticancer Drug Research. Planned start Sep 2014; status: not yet recruiting.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)renal pelvis cancer
Beyond the preview
Go deeper on DRKS00005220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00005220.